CHD1Li 6.11 |
| Catalog No.GC64581 |
CHD1Li 6.11 est un puissant inhibiteur oncogène de CHD1L (IC50 = 3,3 μM pour la protéine recombinante cat-CHD1L). CHD1Li 6.11 est un agent antitumoral biodisponible par voie orale, réduisant considérablement le volume tumoral des xénogreffes de CRC générées À partir de cellules isolées quasi mésenchymateuses (phénotype M), qui possèdent des propriétés tumorigènes améliorées.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2716890-91-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CHD1Li 6.11 is a potent oncogenic CHD1L inhibitor (IC50=3.3 µM for cat-CHD1L recombinant protein). CHD1Li 6.11 is an orally bioavailable antitumor agent, significantly reducing the tumor volume of CRC xenografts generated from isolated quasi mesenchymal cells (M-phenotype), which possess enhanced tumorigenic properties[1].
[1]. Prigaro BJ, et al. Design, Synthesis, and Biological Evaluation of the First Inhibitors of Oncogenic CHD1L. J Med Chem. 2022;65(5):3943-3961.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *